| Primary |
| Drug Use For Unknown Indication |
36.4% |
| Product Used For Unknown Indication |
15.2% |
| Hypertension |
14.0% |
| Type 2 Diabetes Mellitus |
4.1% |
| Atrial Fibrillation |
4.0% |
| Cardiac Failure |
3.1% |
| Oedema |
3.1% |
| Prophylaxis |
3.0% |
| Insomnia |
2.1% |
| Diabetes Mellitus |
1.7% |
| Angina Pectoris |
1.6% |
| Depression |
1.5% |
| Pneumonia |
1.4% |
| Anxiety |
1.3% |
| Constipation |
1.3% |
| Cardiac Failure Congestive |
1.3% |
| Pain |
1.3% |
| Rheumatoid Arthritis |
1.3% |
| Thrombosis Prophylaxis |
1.2% |
| Hypothyroidism |
1.2% |
|
| Renal Failure Acute |
21.8% |
| Renal Failure |
10.5% |
| Syncope |
9.4% |
| Toxic Epidermal Necrolysis |
6.6% |
| Hypokalaemia |
4.4% |
| Hyponatraemia |
4.2% |
| Pseudo-bartter Syndrome |
4.0% |
| Interstitial Lung Disease |
3.9% |
| Stevens-johnson Syndrome |
3.9% |
| Rhabdomyolysis |
3.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.2% |
| Hypotension |
3.1% |
| Pemphigoid |
3.1% |
| Renal Impairment |
3.1% |
| Hyperkalaemia |
2.9% |
| Pancytopenia |
2.9% |
| Fall |
2.6% |
| Thrombocytopenia |
2.4% |
| Dehydration |
2.3% |
| Malaise |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
18.5% |
| Hypertension |
18.4% |
| Drug Use For Unknown Indication |
15.0% |
| Cardiac Failure |
7.0% |
| Oedema |
6.0% |
| Oliguria |
4.7% |
| Prophylaxis |
4.6% |
| Pulmonary Congestion |
4.5% |
| Type 2 Diabetes Mellitus |
2.3% |
| Diabetes Mellitus |
2.2% |
| Atrial Fibrillation |
2.2% |
| Cardiac Failure Congestive |
2.1% |
| Ill-defined Disorder |
1.9% |
| Pain |
1.8% |
| Oedema Peripheral |
1.7% |
| Depression |
1.6% |
| Insomnia |
1.4% |
| Psoriatic Arthropathy |
1.4% |
| Cardiac Failure Chronic |
1.3% |
| Castleman's Disease |
1.3% |
|
| Renal Failure Acute |
19.5% |
| Renal Failure |
10.1% |
| Vomiting |
7.9% |
| Thrombocytopenia |
6.1% |
| Hyponatraemia |
5.5% |
| Toxic Epidermal Necrolysis |
5.0% |
| Renal Impairment |
4.4% |
| Syncope |
4.4% |
| Hypotension |
3.9% |
| Urinary Tract Infection |
3.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.3% |
| Weight Increased |
3.3% |
| Dehydration |
3.2% |
| Rhabdomyolysis |
3.0% |
| Haematuria |
2.9% |
| Pneumonia |
2.9% |
| Orthostatic Hypotension |
2.9% |
| Stevens-johnson Syndrome |
2.8% |
| Interstitial Lung Disease |
2.6% |
| White Blood Cell Count Decreased |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.2% |
| Drug Use For Unknown Indication |
18.5% |
| Hypertension |
11.2% |
| Prophylaxis |
5.5% |
| Pain |
3.8% |
| Diabetes Mellitus |
3.7% |
| Atrial Fibrillation |
3.7% |
| Multiple Myeloma |
2.6% |
| Cardiac Failure |
2.5% |
| Pulmonary Arterial Hypertension |
2.3% |
| Rheumatoid Arthritis |
2.3% |
| Depression |
2.1% |
| Type 2 Diabetes Mellitus |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Constipation |
1.7% |
| Cardiac Disorder |
1.6% |
| Insomnia |
1.6% |
| Osteoporosis |
1.6% |
| Cardiac Failure Congestive |
1.5% |
| Gastrooesophageal Reflux Disease |
1.4% |
|
| Vomiting |
11.8% |
| Weight Decreased |
7.8% |
| Weight Increased |
7.7% |
| Death |
7.0% |
| Pneumonia |
5.9% |
| Renal Failure |
5.8% |
| Renal Failure Acute |
5.0% |
| White Blood Cell Count Decreased |
4.6% |
| Urinary Tract Infection |
4.5% |
| Thrombocytopenia |
4.5% |
| Pain |
4.2% |
| Dyspnoea |
3.9% |
| Oedema Peripheral |
3.9% |
| Respiratory Failure |
3.8% |
| Myocardial Infarction |
3.8% |
| Renal Impairment |
3.4% |
| Pyrexia |
3.3% |
| Sepsis |
3.2% |
| Nausea |
3.1% |
| Rash |
2.8% |
|
| Interacting |
| Product Used For Unknown Indication |
24.4% |
| Hypertension |
19.2% |
| Drug Use For Unknown Indication |
15.5% |
| Cardiac Failure |
10.1% |
| Atrial Fibrillation |
3.7% |
| Cardiomyopathy |
3.0% |
| Gout |
2.6% |
| Diabetes Mellitus |
2.2% |
| Hypertensive Heart Disease |
2.2% |
| Myocardial Ischaemia |
2.2% |
| Essential Hypertension |
1.9% |
| Hypokalaemia |
1.9% |
| Prophylaxis |
1.9% |
| Cardiac Failure Congestive |
1.5% |
| Hypertensive Cardiomyopathy |
1.5% |
| Anxiety |
1.3% |
| Depression |
1.3% |
| Respiratory Tract Infection |
1.3% |
| Arrhythmia |
1.1% |
| Cardiac Failure Chronic |
1.1% |
|
| Renal Failure Acute |
27.9% |
| Drug Interaction |
14.4% |
| Hyponatraemia |
5.8% |
| Respiratory Failure |
5.8% |
| Hyperkalaemia |
4.8% |
| Renal Failure |
3.8% |
| Rhinorrhoea |
3.8% |
| Visual Impairment |
3.8% |
| Asthenia |
2.9% |
| Hypoglycaemia |
2.9% |
| Hypotension |
2.9% |
| Syncope |
2.9% |
| Therapeutic Agent Toxicity |
2.9% |
| Volume Blood Decreased |
2.9% |
| Vomiting |
2.9% |
| Fluid Overload |
1.9% |
| International Normalised Ratio Increased |
1.9% |
| Loss Of Consciousness |
1.9% |
| Orthostatic Hypotension |
1.9% |
| Pain |
1.9% |
|
